SK biopharmaceuticals Co., Ltd.
Financials
Valuation Metrics
SK biopharmaceuticals Co., Ltd.'s Market Cap is ₩6.1T. At end of 2025 it was ₩9.8T. Ranked #87 of 2,405 in KR market (top 4%), #82 of 778 on KOSPI (top 11%), #5 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 6.06T KRW | KR#87/2,405 Sec#5/231 |
| Revenue | 861.34B KRW | KR#444/2,405 Sec#17/231 |
| Net Income | 391.91B KRW | KR#100/2,405 Sec#3/231 |
| Total Assets | 1.20T KRW | KR#432/2,405 Sec#22/231 |
| Net Assets | 826.27B KRW | KR#337/2,405 Sec#20/231 |
| Employees | 265 | KR#888/2,405 Sec#74/231 |
| Value | ||
| P/E | 15.47x | KR#1,107/2,405 Sec#69/231 |
| P/B | 7.34x | KR#2,319/2,405 Sec#205/231 |
| PEG | 0.16x | KR#527/2,405 Sec#32/231 |
| P/S | 7.04x | KR#2,228/2,405 Sec#158/231 |
| EV/EBITDA | 18.98x | KR#1,025/2,405 Sec#59/231 |
| FCF Yield | 2.80% | KR#1,014/2,405 Sec#65/231 |
| Profitability | ||
| ROE | 47.43% | KR#15/2,405 Sec#1/231 |
| ROA | 32.70% | KR#12/2,405 Sec#2/231 |
| Op. Margin | 35.20% | KR#37/2,405 Sec#9/231 |
| Revenue Growth | 38.86% | KR#289/2,405 Sec#33/231 |
| Earnings Growth | 97.64% | KR#400/2,405 Sec#27/231 |
| Financial Health | ||
| Debt Ratio | 45.03% | KR#886/2,405 Sec#102/231 |
| Total Debt | 0 KRW | KR—/2,405 Sec—/231 |
| FCF | 169.44B KRW | KR#127/2,405 Sec#4/231 |
| Cash | 307.77B KRW | KR#191/2,405 Sec#3/231 |
| Current Ratio | 2.72x | KR#622/2,405 Sec#83/231 |
| Net Debt/EBITDA | -1.01x | KR#377/2,405 Sec#20/231 |
| Performance | ||
| 1Y Return | -32.99% | KR#1,590/2,405 Sec#128/231 |
| 1M Return | 2.11% | KR#235/2,405 Sec#26/231 |
| From 52W High | -46.29% | KR#1,010/2,405 Sec#69/231 |
| 1Y MDD | -50.68% | KR#985/2,405 Sec#79/231 |
| Trading | ||
| Volume | 64,015 shares | KR#827/2,405 Sec#91/231 |
| Trading Value | 4.98B KRW | KR#298/2,405 Sec#25/231 |
| Foreign Own. | 12.16% | KR#408/2,405 Sec#32/231 |
| Per Share | ||
| EPS | 5,004 KRW | KR#214/2,405 Sec#11/231 |
| BPS | 10,551 KRW | KR#957/2,405 Sec#64/231 |
Company Info
SK Biopharm was newly established in 2011 through a spin-off of SK Co., Ltd.'s Life Science business division, having initiated new drug research and development in 1993. It launched cenobamate and solriamfetol, treatments for central nervous system epilepsy and sleep disorders, following U.S. FDA approval, and has signed technology export contracts with 17 countries. The company is expanding its CNS capabilities into oncology using RPT and TPD technologies and pursues new drug development through an AI drug design platform and a partnership with LifeSci Venture Partners. SK Biopharm is headquartered in Seongnam-si, Gyeonggi-do.